A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis

Psychoneuroendocrinology

Volumn 38, Issue 5, 2013, Pages 603-611

  Borges, Susana ^a   Gayer Anderson, Charlotte ^a   Mondelli, Valeria ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cortisol; First episode psychosis; Glucocorticoid; HPA axis; Pituitary; Psychosis; Schizophrenia

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE;

CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DISEASE ASSOCIATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM HYPERACTIVITY; MAJOR CLINICAL STUDY; MENTAL STRESS; NEUROENDOCRINE DISEASE; ORGAN SIZE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; DISEASE SUSCEPTIBILITY; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; ORGAN SIZE; PITUITARY GLAND; PITUITARY-ADRENAL SYSTEM; PSYCHOTIC DISORDERS;

EID: 84876081670     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.12.025     Document Type: Review

References (72)

1. Aas M., Dazzan P., Mondelli V., Toulopoulou T., Reichenberg A., Di F.M., Fisher H.L., Handley R., Hepgul N., Marques T., Miorelli A., Taylor H., Russo M., Wiffen B., Papadopoulos A., Aitchison K.J., Morgan C., Murray R.M., Pariante C.M. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol. Med. 2011, 41:463-476.
2. Abel K.M., O'Keane V., Murray R.M. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br. J. Psychiatry 1996, 168:57-60.
3. Aiello G., Horowitz G., Hepgul N., Pariante C.M., Mondelli V. Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with " at risk" mental state. Psychoneuroendocrinology 2012, 37:1600-1613.
4. Axelson D.A., Doraiswamy P.M., Boyko O.B., Rodrigo E.P., McDonald W.M., Ritchie J.C., Patterson L.J., Ellinwood E.H., Nemeroff C.B., Krishnan K.R. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res. 1992, 44:63-70.
5. Belvederi M.M., Pariante C.M., Dazzan P., Hepgul N., Papadopoulos A.S., Zunszain P., Di F.M., Murray R.M., Mondelli V. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 2012, 37:629-644.
6. Bhagwagar Z., Hafizi S., Cowen P.J. Increase in concentration of waking salivary cortisol in recovered patients with depression. Am. J. Psychiatry 2003, 160:1890-1891.
7. Bhagwagar Z., Hafizi S., Cowen P.J. Increased salivary cortisol after waking in depression. Psychopharmacology (Berl.) 2005, 1-4.
8. Brunelin J., d'Amato T., van Os J., Cochet A., Suaud-Chagny M.F., Saoud M. Effects of acute metabolic stress on the dopaminergic and pituitary adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr. Res. 2008, 100:206-211.
9. Buschlen J., Berger G.E., Borgwardt S.J., Aston J., Gschwandtner U., Pflueger M.O., Kuster P., Radu E.W., Stieglitz R.D., Riecher-Rossler A. Pituitary volume increase during emerging psychosis. Schizophr. Res. 2011, 125:41-48.
10. Cahn W., Rais M., Stigter F.P., van Haren N.E., Caspers E., Hulshoff Pol H.E., Xu Z., Schnack H.G., Kahn R.S. Psychosis and brain volume changes during the first five years of schizophrenia. Eur. Neuropsychopharmacol. 2009, 19:147-151.
11. Ceskova E., Kasparek T., Zourkova A., Prikryl R. Dexamethasone suppression test in first-episode schizophrenia. Neuro. Endocrinol. Lett. 2006, 27:433-437.
12. Cleare A.J. The neuroendocrinology of chronic fatigue syndrome. Endocr. Rev. 2003, 24:236-252.
13. Cohrs S., Roher C., Jordan W., Meier A., Huether G., Wuttke W., Ruther E., Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 2006, 185:11-18.
14. Collip D., Nicolson N.A., Lardinois M., Lataster T., van Os J., Myin- Germeys I. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychol. Med. 2011, 41(11):2305-2315.
15. Corcoran C.M., Smith C., McLaughlin D., Auther A., Malaspina D., Cornblatt B. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr. Res. 2012, 135:170-174.
16. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Parellada E., Bernardo M., Kirkpatrick B. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with non-affective psychosis. Schizophr. Res. 2012, 134:16-19.
17. Garner B., Berger G.E., Nicolo J.P., Mackinnon A., Wood S.J., Pariante C.M., Dazzan P., Proffitt T.M., Markulev C., Kerr M., McConchie M., Phillips L.J., Pantelis C., McGorry P.D. Pituitary volume and early treatment response in drug-naive first-episode psychosis patients. Schizophr. Res. 2009, 113:65-71.
18. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., Brewer W.J., Smith D.J., Dazzan P., Berger G.E., Yung A.R., van den B.M., Murray R., McGorry P.D., Pantelis C. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol. Psychiatry 2005, 58:417-423.
19. Garner B., Phassouliotis C., Phillips L.J., Markulev C., Butselaar F., Bendall S., Yun Y., McGorry P.D. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J. Psychiatr. Res. 2011, 45:249-255.
20. Gruner P., Christian C., Robinson D.G., Sevy S., Gunduz-Bruce H., Napolitano B., Bilder R.M., Szeszko P.R. Pituitary volume in first-episode schizophrenia. Psychiatry Res. 2012, 203(1):100-102.
21. Gunduz-Bruce H., Szeszko P.R., Gueorguieva R., Ashtari M., Robinson D.G., Kane J.M., Bilder R.M. Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophr. Res. 2007, 94:281-287.
22. Habets P., Collip D., Myin-Germeys I., Gronenschild E., van Bronswijk S., Hofman P., Lataster T., Lardinois M., Nicolson N.A., van Os J., Marcelis M. Pituitary volume, stress reactivity and genetic risk for psychotic disorder. Psychol. Med. 2012, 42:1523-1533.
23. Hellhammer D.H., Wust S., Kudielka B.M. Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology 2009, 34:163-171.
24. Hempel R.J., Tulen J.H., van Beveren N.J., Röder C.H., de Jong F.H., Hengeveld M.W. Diurnal cortisol patterns of young male patients with schizophrenia. Psychiatry Clin. Neurosci. 2010, 64:548-554.
25. Herz M.I., Fava G.A., Molnar G., Edwards L. The dexamethasone suppression test in newly hospitalized schizophrenic patients. Am. J. Psychiatry 1985, 142:127-129.
26. Hori H., Teraishi T., Ozeki Y., Hattori K., Sasayama D., Matsuo J., Kawamoto Y., Kinoshita Y., Higuchi T., Kunugi Schizotypal personality in healthy adults is related to blunted cortisol responses to the combined dexamethasone/corticotropin-releasing hormone test. Neuropsychobiology 2011, 63:232-241.
27. Jakoveljevic M., Pivac N., Mihaljevic-Peles A., Mustapic M., Relja M., Ljubicic D., Marcinko D., Muck-Seler D. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:399-402.
28. Kale A., Naphade N., Sapkale S., Kamaraju M., Pillai A., Joshi S., Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res. 2010, 175:47-53.
29. Kirschbaum C., Hellhammer D.H. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 1994, 19:313-333.
30. Klomp A., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S., Van Haren N.E. Hypothalamus and pituitary volume in schizophrenia: a structural MRI study. Int. J. Neuropsychopharmacol. 2012, 15:281-288.
31. Lammers C.H., Garcia-Borreguero D., Schmider J., Gotthardt U., Dettling M., Holsboer F., Heuser I.J. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol. Psychiatry 1995, 38:803-807.
32. MacMaster F.P., El-Sheikh R., Upadhyaya A.R., Nutche J., Rosenberg D.R., Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: a pilot study. Schizophr. Res. 2007, 92:207-210.
33. McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000, 886:172-189.
34. Mednick S.A., McNeil T.F. Current methodology in research on the etiology of schizophrenia: serious difficulties which suggest the use of high-risk-group method. Psychol. Bull. 1968, 70:681-693.
35. Mitropolou V., Goodman M., Sevy S., Elman I., New A.S., Iskander E.G., Silverman J.M., Breier A., Siever L.J. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schizophr. Res. 2004, 70:27-31.
36. Mittal V.A., Walker E.F. Minor physical anomalies and vulnerability in prodromal youth. Schizophr. Res. 2011, 129:116-121.
37. Mittal V.A., Dhruv S., Tessner K.D., Walder D.J., Walker E.F. The relations among putative biorisk markers in schizotypal adolescents: minor physical anomalies, movement abnormalities, and salivary cortisol. Biol. Psychiatry 2007, 61(10):1179-1186.
38. Mondelli V., Cattaneo A., Belvederi M.M., Di F.M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72:1677-1684.
39. Mondelli V., Dazzan P., Gabilondo A., Tournikioti K., Walshe M., Marshall N., Schulze K.K., Murray R.M., McDonald C., Pariante C.M. Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology 2008, 33:1004-1012.
40. Mondelli V., Dazzan P., Hepgul N., Di F.M., Aas M., D'Albenzio A., Di N.M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
41. Mondelli V., Pariante C.M., Navari S., Aas M., D'Albenzio A., Di F.M., Handley R., Hepgul N., Marques T.R., Taylor H., Papadopoulos A.S., Aitchison K.J., Murray R.M., Dazzan P. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr. Res. 2010, 119:75-78.
42. Myin-Germeys I., van Os J. Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clin. Psychol. Rev. 2007, 27:409-424.
43. Nicolo J.P., Berger G.E., Garner B.A., Velakoulis D., Markulev C., Kerr M., McGorry P.D., Proffitt T.M., McConchie M., Pantelis C., Wood S.J. The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study. Schizophr. Res. 2010, 116:49-54.
44. Pariante C.M., Dazzan P., Danese A., Morgan K.D., Brudaglio F., Morgan C., Fearon P., Orr K., Hutchinson G., Pantelis C., Velakoulis D., Jones P.B., Leff J., Murray R.M. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005, 30:1923-1931.
45. Pariante C.M. Pituitary volume in psychosis: the first review of the evidence. J. Psychopharmacol. 2008, 22:76-81.
46. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
47. Pariante C.M., Vassilopoulou K., Velakoulis D., Phillips L., Soulsby B., Wood S.J., Brewer W., Smith D.J., Dazzan P., Yung A.R., Zervas I.M., Christodoulou G.N., Murray R., McGorry P.D., Pantelis C. Pituitary volume in psychosis. Br. J. Psychiatry 2004, 185:5-10.
48. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., Popovic S., Miljic N., djurovic M., Jasovic-Gasic M., Diegues C., Casanueva F.F. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
49. Pruessner M., Vracotas N., Joober R., Pruessner J.C., Malla A.K. Blunted cortisol awakening response in men with first episode psychosis: relationship to parental bonding. Psychoneuroendocrinology 2012, (Epub ahead of print).
50. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160:1554-1565.
51. Roberts A.D., Wessely S., Chalder T., Papadopoulos A., Cleare A.J. Salivary cortisol response to awakening in chronic fatigue syndrome. Br. J. Psychiatry 2004, 184:136-141.
52. Roelofs K., Bakvis P., Hermans E.J., van Pelt J., van Honk J. The effects of social stress and cortisol responses on the preconscious selective attention to social threat. Biol. Psychol. 2007, 75:1-7.
53. Rohleder N., Joksimovic L., Wolf J.M., Kirschbaum C. Hypocortisolism and increased glucocorticoid sensitivity of pro-Inflammatory cytokine production in Bosnian war refugees with posttraumatic stress disorder. Biol. Psychiatry 2004, 55:745-751.
54. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
55. Ryan M.C., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004, 74:1999-2008.
56. Ryan M.C., Sharifi N., Condren R., Thakore J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004, 29:1065-1070.
57. Sachar E.J., Kanter S.S., Buie D., Engle R., Mehlman R. Psychoendocrinology of ego disintegration. Am. J. Psychiatry 1970, 126:1067-1078.
58. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
59. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., Kotler M., Weizman A. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr. Res. 2004, 71:427-434.
60. Takahashi T., Wood S.J., Yung A.R., Soulsby B., McGorry P.D., Suzuki M., Kawasaki Y., Phillips L.J., Velakoulis D., Pantelis C. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch. Gen. Psychiatry 2009, 66:366-376.
61. Takahashi T., Zhou S., Nakamura K., Tanino R., Furuichi A., Kido M., Kawasaki Y., Noguchi K., Seto H., Kurachi M., Suzuki M. Longitudinal volume changes of the pituitary gland in patients with schizotypal disorder and first-episode schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:177-183.
62. Tanaka K., Morinbu S., Ichimura M., Asakawa A., Inui A., Hosoda H., Kangawa K., Yamawaki S. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32:1527-1532.
63. Tandon R., Mazzara C., DeQuardo J., Craig K.A., Meador-Woodruff J.H., Goldman R., Greden J.F. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol. Psychiatry 1991, 29:953-964.
64. Upadhyaya A.R., El-Sheikh R., MacMaster F.P., Diwadkar V.A., Keshavan M.S. Pituitary volume in neuroleptic-naïve schizophrenia: a structural MRI study. Schizophr. Res. 2007, 90:266-273.
65. van Venrooij J.A., Fluitman S.B., Lijmer J.G., Kavelaars A., Heijnen C.J., Westenberg H.G., Kahn R.S., Gispen-de Wied C.C. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr. Bull. 2010.
66. Varese F., Barkus E., Bentall R.P. Dissociation mediates the relationship between childhood trauma and hallucination-proneness. Psychol. Med. 2012, 42:1025-1036.
67. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4:189-216.
68. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997, 104:667-685.
69. Walsh P., Spelman L., Sharifi N., Thakore J.H. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005, 30:431-437.
70. Wessa M., Rohleder N., Kirschbaum C., Flor H. Altered cortisol awakening response in posttraumatic stress disorder. Psychoneuroendocrinology 2006, 31:209-215.
71. Yehuda R. Biology of posttraumatic stress disorder. J. Clin. Psychiatry 2001, 62(Suppl. 17):41-46.
72. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.